Chromadex (CDXC) and Cronos Group (CRON) Head to Head Review

Chromadex (NASDAQ:CDXC) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Chromadex and Cronos Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chromadex $21.20 million 9.74 -$11.37 million ($0.35) -10.71
Cronos Group $3.15 million 453.36 $1.92 million $0.01 806.00

Cronos Group has lower revenue, but higher earnings than Chromadex. Chromadex is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.


This table compares Chromadex and Cronos Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -82.82% -65.33% -53.31%
Cronos Group 30.64% 2.23% 2.05%

Institutional and Insider Ownership

16.2% of Chromadex shares are held by institutional investors. Comparatively, 9.7% of Cronos Group shares are held by institutional investors. 10.3% of Chromadex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Chromadex and Cronos Group, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 1 0 3.00
Cronos Group 1 1 2 0 2.25

Chromadex presently has a consensus target price of $8.00, indicating a potential upside of 113.33%. Cronos Group has a consensus target price of $4.50, indicating a potential downside of 44.17%. Given Chromadex’s stronger consensus rating and higher possible upside, analysts plainly believe Chromadex is more favorable than Cronos Group.


Cronos Group beats Chromadex on 7 of the 12 factors compared between the two stocks.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.

Cronos Group Company Profile

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with's FREE daily email newsletter.

Leave a Reply